Oslo-listed Targovax, a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumours, has appointed Lubor Gaal as CFO, effective March 7, 2022. In Targovax, Gaal’s core responsibilities will be…
Oslo-listed Targovax, a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumours, has appointed Lubor Gaal as CFO, effective March 7, 2022. In Targovax, Gaal’s core responsibilities will be…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference